According to a presentation by the company at the 22nd EURETINA World Congress in Hamburg, Germany, the dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.
A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction.
According to a university news release, its CellSight teams clinched top two of three awards in National Eye Institute competition.
According to an OHSA investigator, a study shows changes in patient volume, billing after private equity firms acquire physician practices.
Researchers have found that social media use among physicians jumped during the COVID-19 pandemic, but the role it plays in networking, mentorship and support among ophthalmologists remains unknown.
According to the company, the fully connected environment, digital technologies and artificial intelligence tools enable optimization of patient care.
According to researchers, findings could lead to new screening protocols to catch glaucoma early and preserve vision.
Bausch + Lomb expects to begin the distribution of the intraocular dyes in all EU countries, with the exception of Italy, during the first half of 2023. Bausch + Lomb and Alfa Instruments are also in the process of exploring regulatory requirements and approvals of the surgical dyes in other markets.
David J. Calkins, PhD, is being recognized for his groundbreaking contributions to the field of vision research.
The multi-center, international clinical study is designed to assess the safety and efficacy of novel investigational low-dose atropine eye drops in children 3-17 years old with myopia.
ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases.
The first cases in the United States using the company’s suprachoroidal technology were performed earlier this month, and long-term clinical outcomes will be presented at the annual meeting of the American Academy of Ophthalmology in Chicago, starting Sept. 30.
Researchers at the University of Bonn are evaluating a new imaging technique for the diagnosis of posterior uveitis.
The American Academy of Ophthalmology annual meeting is coming to Chicago, Illinois from September 30 to October 3, featuring Subspecialty Days and a virtual component. The event will be held at Chicago’s McCormick Place, billed as the largest convention center in North America and located on the shore of Lake Michigan.
The company has filed an ophthalmic IND submission for the first treatment of ocular conditions associated with DNA damage.
On this week's episode of the NeuroOp Guru, Andy Lee, MD, and Elizabeth Fortin, MD, discuss Tocilizumab and the influence it can have on ophthalmic outcomes in giant cell arteritis.
AB 2236, which would reduce the medical education, clinical, and surgical training requirements to become licensed in California to perform eye surgery. Trade organizations and other groups are stepping up to oppose the measure.
Researchers in Trinity’s School of Genetics and Microbiology developed a new gene therapy, ophNdi1, that is the first of its kind to directly target mitochondrial function in cells that are malfunctioning in AMD.
Gene therapy has partly restored the function of the retina’s cone receptors in two children who were born completely colorblind, reports a new study led by UCL researchers.
Stoke Therapeutics announced enrollment of the first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy.
Sight Sciences Inc. is taking the wraps off Sion, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
According to the company, results showed increased effects over time with pegcetacoplan, with treatment effect accelerated between months 18 and 24.
Although predefined co-primary study endpoints were not met, AR-15512 demonstrated statistically significant improvements in DED signs, symptoms, and disease-related quality of life.
According to investigators, the progression of myopia in children may be slowed by a metabolite of caffeine, known as 7-MX.
Alcon and Aerie Pharmaceuticals Inc. have announced the companies have entered into a definitive merger agreement through which Alcon will acquire Aerie.
According to the company, topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieve persistent ocular discomfort in severe dry eye disease.
A test to detect and quantify TDP-43 deposits in the retina provides this capability for the first time and can be performed using commercially available and widely utilized diagnostic cameras.
In embryonic stages, tactile stimuli simultaneously activate tactile and visual neural pathways. Shortly after birth, both pathways reorganize to allow separate processing of touch and vision. The change of pathway is facilitated by the activity waves of the retina, which act as railroads that direct the stimuli of each sensory modality to the corresponding cortex, so that we can perceive them separately.
APOE4 gene associated with Alzheimer’s disease risk was found to protect mice from glaucoma. Research team also prevented retinal ganglion cell death by blocking the APOE signaling pathway, pointing to a potential treatment strategy for glaucoma.
.png "Optometry Times"){kind=logo}
